MX2020003413A - Preparacion y almacenamiento de formulaciones liposomales de arn adecuadas para terapia. - Google Patents

Preparacion y almacenamiento de formulaciones liposomales de arn adecuadas para terapia.

Info

Publication number
MX2020003413A
MX2020003413A MX2020003413A MX2020003413A MX2020003413A MX 2020003413 A MX2020003413 A MX 2020003413A MX 2020003413 A MX2020003413 A MX 2020003413A MX 2020003413 A MX2020003413 A MX 2020003413A MX 2020003413 A MX2020003413 A MX 2020003413A
Authority
MX
Mexico
Prior art keywords
rna
therapy
preparation
storage
present disclosure
Prior art date
Application number
MX2020003413A
Other languages
English (en)
Inventor
Heinrieh HAAS
Sebastian Horner
Borquez Isaae Hernan Esparza
Thomas Michael Hiller
Ferdia Bates
Original Assignee
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE filed Critical BioNTech SE
Publication of MX2020003413A publication Critical patent/MX2020003413A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1277Processes for preparing; Proliposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente descripción se relaciona con un método para preparar partículas de lipoplejo-ARN para el suministro de ARN a los tejidos objetivo, después de la administración parenteral, en particular después de la administración intravenosa, y las composiciones que comprenden tales partículas de lipoplejo-ARN. La presente descripción también se relaciona con métodos que permiten preparar las partículas de lipoplejo-ARN de una manera industrial que cumple con las GMP. Además, la presente descripción se relaciona con un método y con composiciones para almacenar las partículas de lipoplejo-ARN sin la pérdida sustancial de la calidad del producto y en particular, sin la pérdida sustancial de la actividad del ARN.
MX2020003413A 2017-10-20 2018-10-18 Preparacion y almacenamiento de formulaciones liposomales de arn adecuadas para terapia. MX2020003413A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762574965P 2017-10-20 2017-10-20
PCT/EP2018/078587 WO2019077053A1 (en) 2017-10-20 2018-10-18 PREPARATION AND STORAGE OF APPROPRIATE LIPOSOMAL RNA FORMULATIONS FOR THERAPY

Publications (1)

Publication Number Publication Date
MX2020003413A true MX2020003413A (es) 2020-07-20

Family

ID=63965663

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003413A MX2020003413A (es) 2017-10-20 2018-10-18 Preparacion y almacenamiento de formulaciones liposomales de arn adecuadas para terapia.

Country Status (16)

Country Link
US (2) US11395799B2 (es)
EP (2) EP3697384A1 (es)
JP (2) JP2021500324A (es)
KR (1) KR20200100619A (es)
CN (3) CN111246845A (es)
AR (2) AR113782A1 (es)
AU (2) AU2018350846B2 (es)
BR (1) BR112020007470A2 (es)
CA (1) CA3078292A1 (es)
IL (1) IL273852A (es)
MX (1) MX2020003413A (es)
RU (1) RU2022103533A (es)
SG (1) SG11202002579SA (es)
TW (2) TW202146031A (es)
WO (1) WO2019077053A1 (es)
ZA (1) ZA202001675B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至her2結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
RS65204B1 (sr) 2017-03-02 2024-03-29 Genentech Inc Adjuvansni tretman her2-pozitivnog raka dojke
SG11202002579SA (en) 2017-10-20 2020-05-28 Biontech Rna Pharmaceuticals Gmbh Preparation and storage of liposomal rna formulations suitable for therapy
EP3740241A1 (en) * 2018-01-18 2020-11-25 eTheRNA Immunotherapies NV Lipid nanoparticles
WO2020200472A1 (en) * 2019-04-05 2020-10-08 Biontech Rna Pharmaceuticals Gmbh Preparation and storage of liposomal rna formulations suitable for therapy
CN116648303A (zh) 2020-09-08 2023-08-25 基因泰克公司 用于使用蠕动泵和阻尼器来生产药物组合物的系统和方法
TW202228727A (zh) * 2020-10-01 2022-08-01 德商拜恩迪克公司 適用於治療之微脂體rna調配物之製備及儲存
WO2022182767A1 (en) * 2021-02-23 2022-09-01 Nature's Toolbox, Inc. Lipid nanoparticle (lnp) encapsulation of mrna products
EP4334943A1 (en) 2021-05-04 2024-03-13 BioNTech SE Technologies for early detection of variants of interest
CA3223943A1 (en) 2021-07-29 2023-02-02 Ugur Sahin Compositions and methods for treatment of melanoma
WO2023057596A1 (en) 2021-10-06 2023-04-13 Leon-Nanodrugs Gmbh Method for preparing lipid nanoparticles
CN114601747A (zh) * 2022-03-07 2022-06-10 广州市万千粉丝化妆品有限公司 一种催生蛋白及rna具有延长细胞端粒和增殖的核蛋白端粒酶在化妆品中的应用
WO2024011033A1 (en) 2022-07-07 2024-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogens and methods for inducing an immune response
WO2024056856A1 (en) 2022-09-15 2024-03-21 BioNTech SE Systems and compositions comprising trans-amplifying rna vectors with mirna

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60017406T2 (de) * 1999-07-15 2005-09-29 Inex Pharmaceuticals Corp., Burnaby Verfahren zur herstellung von in lipid verkapselten therapeutischen wirkstoffen
DE10109897A1 (de) 2001-02-21 2002-11-07 Novosom Ag Fakultativ kationische Liposomen und Verwendung dieser
CA2469623C (en) * 2001-12-12 2012-05-29 F H Faulding & Co Limited Composition for the preservation of viruses
US7008403B1 (en) 2002-07-19 2006-03-07 Cognitive Ventures Corporation Infusion pump and method for use
JP4987474B2 (ja) * 2003-06-04 2012-07-25 ジョージタウン・ユニバーシティ リポソーム複合体の安定性および使用期限を改良するための方法
EP1512393A1 (de) * 2003-09-08 2005-03-09 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Verfahren zur Herstellung von homogenen Liposomen und Lipoplexen
WO2009111088A2 (en) * 2008-01-02 2009-09-11 The Johns Hopkins University Antitumor immunization by liposomal delivery of vaccine to the spleen
EP2328919A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
WO2011127255A1 (en) * 2010-04-08 2011-10-13 Merck Sharp & Dohme Corp. Preparation of lipid nanoparticles
EP2675918B1 (en) 2011-02-15 2017-11-08 Merrimack Pharmaceuticals, Inc. Compositions and methods for delivering nucleic acid to a cell
CN102144973A (zh) * 2011-03-31 2011-08-10 中国药科大学 一种优化的siRNA阳离子脂质体的处方组成
CN102727436A (zh) * 2011-04-15 2012-10-17 百奥迈科生物技术有限公司 核酸脂质体药物制剂
AU2012330819B2 (en) * 2011-11-04 2017-08-31 Nitto Denko Corporation Single use system for sterilely producing lipid-nucleic acid particles
WO2013143555A1 (en) * 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
PL3427723T3 (pl) 2012-03-26 2021-01-11 Biontech Rna Pharmaceuticals Gmbh Preparat rna do immunoterapii
CN103194489B (zh) * 2013-03-26 2015-09-30 中国科学院过程工程研究所 新型阳离子脂质体核酸类药物制剂,及其制备方法和应用
WO2015024664A1 (en) * 2013-08-21 2015-02-26 Curevac Gmbh Composition and vaccine for treating prostate cancer
JP6363179B2 (ja) * 2013-09-26 2018-07-25 バイオンテック アーゲー Rnaによるシェルを含む粒子
WO2016045732A1 (en) * 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
CN107533076A (zh) * 2015-02-24 2018-01-02 不列颠哥伦比亚大学 连续流微流体系统
CN107427791B (zh) * 2015-03-19 2021-05-14 康涅狄格大学 用于连续制造脂质体药物制剂的系统和方法
WO2016155809A1 (en) * 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell
SG11202002579SA (en) 2017-10-20 2020-05-28 Biontech Rna Pharmaceuticals Gmbh Preparation and storage of liposomal rna formulations suitable for therapy

Also Published As

Publication number Publication date
RU2022103533A (ru) 2022-03-10
AU2018350846A1 (en) 2020-04-23
KR20200100619A (ko) 2020-08-26
ZA202001675B (en) 2021-07-28
BR112020007470A2 (pt) 2020-10-27
AU2023201185A1 (en) 2023-04-06
AU2018350846B2 (en) 2022-12-08
IL273852A (en) 2020-05-31
SG11202002579SA (en) 2020-05-28
JP2023052184A (ja) 2023-04-11
AR127361A2 (es) 2024-01-17
TW202146031A (zh) 2021-12-16
JP2021500324A (ja) 2021-01-07
TW201927288A (zh) 2019-07-16
CN114392233A (zh) 2022-04-26
AR113782A1 (es) 2020-06-10
RU2020113577A (ru) 2021-11-22
RU2020113577A3 (es) 2022-02-16
EP3697384A1 (en) 2020-08-26
CN111246845A (zh) 2020-06-05
CA3078292A1 (en) 2019-04-25
US20210161818A1 (en) 2021-06-03
US11395799B2 (en) 2022-07-26
US20200246267A1 (en) 2020-08-06
CN114344486A (zh) 2022-04-15
WO2019077053A1 (en) 2019-04-25
EP3858333A1 (en) 2021-08-04

Similar Documents

Publication Publication Date Title
MX2020003413A (es) Preparacion y almacenamiento de formulaciones liposomales de arn adecuadas para terapia.
MX2021012138A (es) Preparacion y almacenamiento de formulaciones de arn liposomico adecuadas para terapia.
AU2016343803A8 (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2019036008A8 (en) Lipids for use in lipid nanoparticle formulations
WO2014205317A3 (en) Cyclic peptides as protein targeting agents
NZ732777A (en) Ionizable cationic lipid for rna delivery
WO2015184256A3 (en) Biodegradable lipids for delivery of nucleic acids
PH12017500367A1 (en) Compounds that inhibit mcl-1 protein
PH12021551189A1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
MX2022006512A (es) Lipidos cationicos de trialquilo y metodos de uso de los mismos.
MX2021002220A (es) Forma cristalina de base libre de lorlatinib.
EP3659585A4 (en) COMPOSITION FOR ADMINISTERING PHYSIOLOGICALLY ACTIVE SUBSTANCES INTO A BLOOD VESSEL
MX2018002627A (es) Metodo de cristalizacion y biodisponibilidad.
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
NZ725044A (en) Compounds and compositions for inducing chondrogenesis
MX2019000381A (es) Formulacion para la administracion de arn.
WO2015048757A3 (en) Foam formulations and apparatus for delivery
EP4233896A3 (en) Method for preparing an immunogenic lysate, the lysate obtained, dendritic cells loaded with such lysate and a pharmaceutical composition comprising the lysate or the dendritic cells
MX360315B (es) Composiciones farmaceuticas que comprenden un inhibidor de aromatasa.
MX2019001579A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
WO2017098051A3 (en) Combined preparations of pkm2 modulators and hmgb1
MX2017009289A (es) Formulaciones farmaceuticas que comprenden cangrelor de alta pureza y metodos para preparar y utilizar las mismas.
WO2017091767A3 (en) Drug formulations for cancer treatment
WO2016205397A3 (en) Target-specific delivery of therapeutic agents